NOVARTIS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 92.32 CHF | +1.97% |
|
+4.94% | +8.78% |
| 10/05 | Novartis’ Scemblix Gets Third US FDA Breakthrough Therapy Designation | MT |
| 10/05 | Novartis Gets FDA Breakthrough Therapy Designation for Scemblix | DJ |
ETFs positioned on Novartis AG
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 10.40% | 121 M€ | -.--% | ||
| 5.57% | 0 M€ | +7.69% | - | |
| 4.12% | 88 M€ | +10.37% | - | |
| 3.79% | 2 M€ | -25.75% | ||
| 2.70% | 4 M€ | -.--% | - | |
| 2.55% | 6 M€ | -.--% | ||
| 2.53% | 6 M€ | -.--% | - | |
| 2.00% | 3 M€ | +9.95% | - | |
| 1.50% | 0 M€ | +7.24% | - | |
| 1.44% | 29 M€ | +8.37% | - | |
| 1.43% | 2 M€ | -.--% | - | |
| 1.43% | 2 M€ | +9.19% | - | |
| 1.41% | 0 M€ | +8.19% | ||
| 1.20% | 0 M€ | +9.46% | ||
| 1.15% | 10 M€ | -3.35% | - | |
| 1.00% | 0 M€ | +4.81% | - | |
| 0.98% | 7 M€ | +0.11% | - | |
| 0.74% | 0 M€ | +3.57% | ||
| 0.71% | 5 M€ | -.--% | - | |
| 0.53% | 284 M€ | -.--% |
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows:
- oncology (29.9%);
- immunology (17.2%);
- cardiovascular, renal and metabolic diseases (14.1%);
- neuroscience (8.9%).
The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products.
At the end of 2023, Novartis AG had 33 production sites worldwide.
Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
101.8
USD
Average target price
108.4
USD
Spread / Average Target
+6.52%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.78% | 208B | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| -7.93% | 200B | |
| +7.68% | 166B | |
| -2.71% | 159B |
- Stock Market
- Equities
- NOVN Stock
- Funds and ETFs Novartis AG
